Monte Rosa Therapeutics Q1 2024 Earnings Report $7.67 -0.01 (-0.13%) (As of 12/17/2024 ET) Earnings HistoryForecast Monte Rosa Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.56Beat/MissBeat by +$0.03One Year Ago EPSN/AMonte Rosa Therapeutics Revenue ResultsActual Revenue$1.06 millionExpected Revenue$4.29 millionBeat/MissMissed by -$3.23 millionYoY Revenue GrowthN/AMonte Rosa Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call ResourcesPress ReleaseGLUE Earnings HistoryPowered by Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Monte Rosa Therapeutics Earnings HeadlinesMonte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of DirectorsDecember 13, 2024 | globenewswire.comMonte Rosa Therapeutics presents preclinical data on CDK2 degraderDecember 11, 2024 | markets.businessinsider.comForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersDecember 11, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerDecember 11, 2024 | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 8.7% - Should You Buy?December 8, 2024 | americanbankingnews.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.View Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
